Novo’s blockbuster drugs could pull it into buzzier areas of healthcare, chief executive Mike Doustdar said, as the Ozempic maker seeks to lessen its reliance on obesity and diabetes.
Novo’s blockbuster drugs could pull it into buzzier areas of healthcare, chief executive Mike Doustdar said, as the Ozempic maker seeks to lessen its reliance on obesity and diabetes.